Market Overview

UPDATE: Jefferies Raises PT on Merck & Co. on Positive Outlook

Share:
Related MRK
Merck Gets Breakthrough Therapy Status From FDA And PRIME Status From EMA For Investigational Ebola Zaire Vaccine
Merck Presents Data On Its Investigational Once-Daily Formulation Of ISENTRESS
Biotech Forum Daily Digest: Will Biotech Finally Break Out? All Eyes On Gilead, Spotlight On Seres Therapeutics (Seeking Alpha)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Merck & Co. (NYSE: MRK), and raised the price target from $46.00 to $48.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Merck & Co. closed on Tuesday at $45.51.

Latest Ratings for MRK

DateFirmActionFromTo
Jul 2016BMO CapitalDowngradesOutperformMarket Perform
Jul 2016JefferiesMaintainsHold
Jun 2016JefferiesMaintainsHold

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (MRK)

View Comments and Join the Discussion!